Lixisenatide was associated with a statistically significant reduction in 2-h postprandial plasma glucose after a standardized breakfast versus placebo ( LS mean difference : -4.28 mmol/L , p < 0.0001 ) and a significant reduction in fasting plasma glucose ( p = 0.0109 ) .